BioMarin To Raise $850 Mln In Sr. Notes To Fund Amicus Acquisition

BioMarin announced a financing package to fund its pending acquisition of Amicus, including an $850 million offering of senior unsecured notes due 2034, a $2.0 billion senior secured Term Loan B, an $800 million Term Loan A, and a $600 million revolving credit facility (with up to $150 million potentially borrowable under the revolver for transaction costs). Proceeds from the notes and new term facilities, together with cash on hand, will be held in escrow until the deal is expected to close by December 19, 2026, and the notes must be redeemed at par plus accrued interest if the acquisition is not completed or certain events occur. Shares were trading down in pre-market after recent weakness, reflecting investor concern over the large debt-funded transaction and near-term execution risk.

Analysis

Market structure: BioMarin’s $850m unsecured note + $2.8bn term loans materially increases debt supply and shifts near-term financing risk onto debt markets; note escrow/redemption mechanics reduce noteholder risk but raise refinancing/liquidity stress for BMRN equity and bank lenders. Direct winners: lenders and syndication banks that will earn fees; losers: BMRN equity holders (shares down ~3%) and marginal high-yield/leveraged loan investors if spreads reprice. Cross-asset: expect BMRN credit spreads to widen vs. biotech peers, upward pressure on equity implied volatility, and temporary outflows from biotech loans/ETF sleeves into cash or defensive bond funds.

Risk assessment: Tail risks include deal failure (forced note redemption by 12/19/2026), a ratings downgrade that accelerates covenants, or syndicated loan market pullback forcing repricing >200–300bp higher. Immediate (days) risks: volatility and equity downside around syndication updates; short-term (weeks/months): syndication repricing or covenant tightening; long-term (quarters/years): higher leverage compressing R&D and EPS. Hidden dependencies: escrowed proceeds mask de facto leverage until close and the revolving carve-out ($150m) can be tapped, changing liquidity profile rapidly.

Trade implications: Primary tactical trade is directional short BMRN equity/credit and relative long FOLD (acquisition target) as arbitrage, sizing 2–4% notional with protection. Use option structures to cap downside: buy 9–15 month BMRN put spreads (e.g., buy 12‑month 45p / sell 30p) to express >20% downside scenario while selling covered calls on FOLD or buying FOLD call spreads to capture deal premium erosion. Credit investors: avoid participating in BMRN new‑issue term loans unless spread pickup >200bp vs. comparable biotech BB loans.

Contrarian angles: Consensus focuses on leverage; underappreciated is the escrow redemption clause which caps debt-holder loss and may reduce actual default risk — equity reaction may be overdone if deal closes. Historical parallel: 2019 biotech buyouts where acquirer equity dropped ~10% into financing then recovered after close — if syndication completes at reasonable coupons, BMRN equity could rebound 15–25% within 6–12 months. Unintended consequence: aggressive short in BMRN before syndication fills could be painful if banks aggressively underwrite and absorb paper, so size and option protection matter.

Key Decisions for Investors

• Establish a paired trade: long FOLD (target 3% portfolio weight) and short BMRN (2% weight) through equity or options; hold until deal close target date 12/19/2026, re-evaluate on any material change in deal terms or if spread between FOLD market price and announced consideration >3%.
• Buy BMRN downside protection via a 12‑month put spread (example size 2–3% notional): buy 2027-Jan 45 put and sell 2027-Jan 30 put (or nearest strikes) to cap cost and express >20% downside; unwind if BMRN implied vol rises >40% or if syndication priced with coupons tight enough to compress credit spread by >150bp.
• Credit action: avoid new‑issue BMRN Term Loan B allocations and refuse bilateral loan participation unless spread compensates with >=200–300bp pickup versus peer BB biotech loans; consider buying short-dated protection (CDS) if BMRN senior spreads widen above 500bp as a directional hedge (reassess at 60 days).
• Event triggers to watch (monitor within 30–90 days): syndicated loan pricing updates, S&P/Moody’s rating/watch announcements, and any change to the escrow/redemption language; if a downgrade/watch occurs, increase short BMRN sizing by 50% and trim long FOLD by 50%.